|
Pegfilgrastim
resources
|
|
|
|
|
|
DRUG INFO
Pegfilgrastim
Drug Name:
Pegfilgrastim
Indication: Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant
Pharmacology: Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.
Mechanism Of Action: Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase
Drug Category: Immunomodulatory Agents; Anti-infective Agents; Antineutropenic Agents; hematopoietic agents (20:16.00)
Brand Names/Synonyms: Granulocyte colony-stimulating factor precursor;G-CSF;Pluripoietin;Filgrastim;Lenograstim; Neulasta (Amgen Inc.)
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: PEGylated human granulocyte colony stimulating factor
Chemical Formula: C845H1343N223O243S9
Half Life: 15-80 hrs
Drug Type: Approved Drug
# Accession No: BIOD00094
CAS Registry Number: 208265-92-3
|
|
|
|
|
|
Pegfilgrastim News
(When available)
|
|
|
